Find your next great investment using Simply Wall St’s simple yet powerful screeners, trusted by over 7 million individual investors worldwide.
Cosmo Pharmaceuticals (SWX:COPN) has been in the spotlight after posting huge total returns over the past three years, prompting investors to reassess how its gastroenterology and dermatology portfolio fits into its healthcare business.
See our latest analysis for Cosmo Pharmaceuticals.
Over the past year, Cosmo Pharmaceuticals has posted a 90-day share price return of 76.6% and a total shareholder return of 76.5%, but its recent one-day drop of 2.5% to CHF 116.2 suggests investors are reassessing how much recent optimism the stock has reflected.
If Cosmo’s move has you rethinking your healthcare exposure, now might be a good time to expand your horizons and check out the 112 healthcare AI stocks we’ve screened as potential next ideas.
After years of strong growth, with the share price close to analyst targets, the key question now is whether Cosmo is still trading below its revenue of €182.271 million and net profit of €59.991 million, or whether the market has already priced in future growth.
Cosmo Pharmaceuticals last closed at CHF 116.20, and according to kapirey, the most popular narrative among Simply Wall St users suggests its fair value is CHF 87.47, well below the market price.
The company’s report on March 6 sent shares down 20% on expectations of lower revenue through December 2025 without a commercial agreement on new products. This makes me cautious and lower my 3-year growth forecast in the absence of more information.
Read the full account.
Curious what’s behind the lower fair value? That argument is based on expectations for slower revenue growth, tighter profit assumptions and future P/E ratios well below recent market enthusiasm.
Result: Fair value of CHF 87.47 (overvalued)
Read the narrative in full and learn what’s behind the predictions.
However, new licensing deals or varying results from late-stage trials could quickly change growth expectations and challenge cautious fair value views.
Understand the key risks described by Cosmo Pharmaceuticals.
The user narrative’s fair value of CHF 87.47 pales in comparison to our SWS DCF model, which suggests a future cash flow value of CHF 1,092.51 per share and suggests that Cosmo is trading at a significant discount. When one model suggests possible overestimation and another suggests deep value, which set of assumptions deserves greater weight?
